

AD \_\_\_\_\_

Award Number: DAMD17-02-1-0312

TITLE: RIZ Tumor Suppressor and Breast Cancer: The PR Domain

PRINCIPAL INVESTIGATOR: Celine Aznar-Derunes, Ph.D.

CONTRACTING ORGANIZATION: The Burnham Institute  
La Jolla, California 92037

REPORT DATE: May 2003

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030930 042

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

<b>1. AGENCY USE ONLY</b> (Leave blank)		<b>2. REPORT DATE</b> May 2003	<b>3. REPORT TYPE AND DATES COVERED</b> Annual Summary (1 May 02 - 30 Apr 03)	
<b>4. TITLE AND SUBTITLE</b> RIZ Tumor Suppressor and Breast Cancer: The PR Domain			<b>5. FUNDING NUMBERS</b> DAMD17-02-1-0312	
<b>6. AUTHOR(S)</b> Celine Aznar-Derunes, Ph.D.				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> The Burnham Institute La Jolla, California 92037  E-Mail: cderunes@burnham.rg			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b>				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited				<b>12b. DISTRIBUTION CODE</b>
<b>13. ABSTRACT (Maximum 200 Words)</b>  Mutations or changes in normal cellular genes are generally linked to human cancer. Multiple gene changes involving at least two types of cancer genes, protooncogenes and tumor suppressor genes, are required for the clonal expansion of a malignant cell. The RIZ gene plays an important role in human cancer and more particularly in breast cancer. RIZ is the founding member of the PR-domain family of zinc finger genes. Two protein products are produced from the RIZ gene which differ by the presence or the absence of the PR domain : RIZ1 and RIZ2. RIZ1 is commonly lost or underexpressed in tumors whereas RIZ2 is always present. RIZ1 is a tumor suppressor whereas RIZ2 is not.  In this project, we are trying to characterize the structural and the functional role of the RIZ1-PR and/or related domains using protein crystallography. Our goal is to understand the tumor-suppression mechanism of RIZ1 and PR-proteins in breast cancer. This will provide us new tools for possible treatment in breast cancer.				
<b>14. SUBJECT TERMS</b> Tumor suppressor, crystallography, methyltransferase				<b>15. NUMBER OF PAGES</b> 10
				<b>16. PRICE CODE</b>
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

## Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	5
Key Research Accomplishments.....	8
Reportable Outcomes.....	8
Conclusions.....	8
References.....	9
Appendices.....	

# INTRODUCTION

The retinoblastoma interacting zing finger (RIZ) gene was isolated originally in a functional screen for proteins that bind to the retinoblastoma (Rb) tumor suppressor (1). RIZ maps to the human chromosome band 1p36.23 (2,3). This region commonly undergoes deletions, rearrangements or loss of heterozygosity in tumors including human mammary cancer (4).

RIZ is the founding member of the PR-domain family zinc finger genes. It contains an Rb-binding motif called the AR domain similar to the E1A viral oncoprotein (5), eight zinc finger motifs, some GTPase and SH3 domains and a PR domain at its N-terminus (6, 7, 8, 9). The RIZ gene normally produces two different protein products, RIZ1 and RIZ2, which respectively differ in length by the presence or the absence of the PR domain. RIZ2 is produced by an internal promoter (7). RIZ1 is a tumor suppressor whereas RIZ2 is not. RIZ1 expression is commonly lost in human breast cancer tumors as well as in several other types of tumor examined (9). In contrast, RIZ2 is uniformly expressed in all cases examined. So there may be a specific negative selection for RIZ1 versus RIZ2 in tumors.

We are focusing on the PR domain of RIZ1 which plays a role in tumorigenesis in breast cancer. The PR domain is composed of approximately 100 amino-acids and is conserved in a subfamily of kruppel-like zinc finger genes. Other members of the PR family include the MDS1-EVI1 breakpoint gene involved in human leukemia and the PRDI-BF1 or BLIMP1 transcription repressor, which can active B-cell maturation (10-13). Different observations suggest that PR genes or the PR-containing product of these genes are the negative regulators of cell growth and tumorigenesis. A common function of the PR domain is to mediate protein-protein interaction. The PR domain of RIZ1 is a protein-binding interface (6). Binding is mediated by residues conserved among different PR domains suggesting that similar functions may be shared among them.

The PR domain was found to be homologous to the SET domains (6) which have recently been shown to mediate protein-protein interaction too (14, 15). PR and SET domains are important in tumor suppression and define a new class of tumor suppressor genes (16). Furthermore, PR proteins may function in chromatin-mediated control of gene expression as inferred from the homology with SET proteins (6).

Now, we have successfully produced milligram amounts of pure RIZ1-PR domain and this protein has been introduced into crystallization trials in order to solve its structure. Our long term goal is to determine the crystal structure of this domain in order to provide us a new, innovative tool for diagnostic purposes or possible treatment in breast cancer.

# BODY

## Task 1 : To construct a stable RIZ PR domain.

### a) Computer modeling/threading:

The PR domain shares sequence homology with the SET domain (6).

		BOX A		BOX B
SET CONTAINING				
SUV39HI	253	GRGWGVRTLEKIRKNSFVMEYVGEIITSEE-	(24)	-VYTVDAAY--GNISHFVNHSCDPNLQVYNVFID-
EZH2	621	VAGWGIFIKDPVQKNEFTSEYCGEIIISQDE-	(21)	-DFVVDATRK--GNKIRFANHSVNPNCYAKVMMVNG
MLL1	3838	IHGRGLFCKRNIDAGEMVIEYAGNVIRSIQ-	(22)	-EV-VDATMH--GNRARFINHSCEPNCYSRVINIDG
PR CONTAINING				
BLIMP1	60	EEVIGVMSKEYIPKGTREFGPLIGEIYTNDT-	(19)	-HHFIDGFNEEKSNNMRYVNPAPHSPREQNLAAQON-
RIZ1	39	KTRIGVWATKPILKGKKEFGFVGDKKRSQ-	(16)	-WMCIDATDPEKGNWLRVYNWACSGEEQNIFFLEI-
		BOX C		
SET CONTAINING				
SUV39HI	253	(7)-RIAFF-ATRTIRAGEELTFDYNMQVDPVD		
EZH2	621	--DHRIGIF-AKRAIQTGEELFFDYRSQADAL		
MLL1	3838	--QKHIVIF-AMRKIYRGEELTYDYKFPIEDAS		
PR CONTAINING				
BLIMP1	60	--GMNIY-FYTIKPIPANQELLVWYCRDFAERL		
RIZ1	39	--NRAIY-YKTLKPIAPGEELLVWYNGEDNPEI		

In a comparison between the sequences, the Box C region is the most conserved. The main differences lie in the boxes A and B in which the PR domain has several conserved motifs that are not found in SET.

Very recently, some SET domain structures were able to be found in the literature (17-22). Generally speaking, the SET domain is rich in  $\beta$ -conformation : it consists of several small  $\beta$ -sheets, each containing a few short strands. The SET domain is most characterized by turns and meandering loops. The C-terminal region is a knot-like structure : the C-terminal segment passes through a loop. This particular structure is the most highly conserved sequence motif in the SET family and must certainly play a critical role in binding and catalysis. The structurally conserved core of the SET domain appears to be made up of two discontinuous parts of the primary sequence. These two parts are interrupted by a highly variable segment which differs in every structure.

We tried to build a homology model of our RIZ1-PR domain based on the different structures of SET domains and the general shape is the same, but we expect that the real structure of the PR domain will certainly be different in some points from the SET domain. This difference should be seen, more particularly, in the variable segment, because the sequence similarity between PR and SET domains is typically 20-30% amino acid identity. This percentage corresponds to the limit for a homology model validation.

### b) Protein expression and purification

The GST-fusion construct of the PR sequence of RIZ1 was prepared by our collaborator Dr Shi HUANG at the Burnham Institute. After purification by affinity chromatography on a glutathione-agarose column and by ion-exchange chromatography on a Q-Sepharose column, we have obtained a good amount of protein to induce crystallization trials.

## **Task 2 : To crystallize the RIZ PR domain.**

### a) Crystallization trials :

We started crystallization trials as soon as we had purified the protein. We used first pre-made crystallization kits from Hampton-Research (Crystal screens I and II) and Emerald Biostructure (Wizard I and II) or our own crystallization systems (changing temperature, concentration...). Up to this time we have not been able to detect any crystals.

In order to increase the chances to crystallize the protein, we sent a sample of our protein to a facility for high throughput screening testing ~1500 conditions. For the moment we don't have the result of these searches.

More of that, the SET domain structures were done in presence of co-factors : the S-adenosylmethionine (SAM) and the S-adenosylhomocysteine (AdoHcy) (17-22). So we will try to crystallize the RIZ1 PR domain in presence of these two co-factors. They could help to stabilize the protein structure using its natural ability for methylation.

## **Task 3 : To solve the crystal structure of RIZ PR domain.**

This part depends on the task 2, so we did not begin this part.

## **Task 4 : To solve the crystal structure of related PR domains.**

We are working too on two other proteins: the BLIMP-PR from the same family as the RIZ1-PR domain and a longer construct of the RIZ1 protein. This last protein is particularly of interest because nobody has done a structure of this type until right now. All the constructs were produced by the Dr Shi HUANG laboratory.

### a) Protein expression, purification, characterization

- BLIMP-PR called BLPR

The PR domain of BLIMP has been made as a GST-fusion protein. The overexpression and purification of this protein is already done and we have this protein at a 25 mg/ml concentration.

- RIZ1 protein

A GST-fusion construct was prepared. The purification of the longer RIZ1 construct was difficult because of the degradation of the protein by a protease during the process and particularly during the thrombin cutting. After some analysis of the degradation products by mass spectroscopy and amino-acid analysis, we have discovered that the protein was degraded between the PR and the AR domains. The PR domain obtained in this way is not very well folded as shown by NMR and light scattering experiments.

So we asked Dr Shi Huang to prepare a His-tagged RIZ1 in order to avoid the degradation during the purification steps. This time, the process does not include a thrombin cutting. But the result was the same and the yield of the overexpression was lower.

The next step will be to produce a GST-fusion mutated RIZ1. The mutations that we plan to do correspond to the amino-acid where the degradation occurs. But we will also mutate other residues in this region. Some activity tests will be done in order to ensure that the mutations do not affect the activity of RIZ1 concerning the methylation of the Histone 3. We expect to avoid the RIZ1 degradation and to be able to obtain a good quantity of the RIZ1 protein to put it in the crystallization trials.

b) Crystallization trials

Right now, as we have the BLPR protein in good quantity, we will try to crystallize it with and without the two co-factors SAM and AdoHcy. We will try the Hampton screening and the Emerald Biostructure kits and more particularly the conditions which contain a high salt concentration as it worked for the other SET domains. We will try the high throughput screening too.

## **KEY RESEARCH ACCOMPLISHMENTS**

- Molecular modeling of the RIZ1-PR domain
- Overexpression and purification of the RIZ PR domain used for crystallization trials
- Overexpression and purification of the BLPR domain

## **REPORTABLE OUTCOMES**

None

## **CONCLUSIONS**

During the first 10 months of our research, we have successfully engineered two PR domains belonging to the same family of protein : the RIZ1-PR domain (163 amino acids) and the BLPR protein (198 amino acids). These two proteins were or will be introduced to crystallization trials which will allow us to determine their 3D structures. Concerning the 3D structure, we have built a homology model of the RIZ1- PR domain. Then we have designed a mutated construct of a longer segment of the RIZ1 protein which hopefully will lead us to succeed in its structural studies.



## **BIBLIOGRAPHY**

- 1 – Buyse I., Shao G. and Huang S.: The retinoblasma protein binds to RIZ, a zinc finger protein that shares an epitope with the adenovirus E1A protein. *Proc. Natl. Acad. Sci. USA* **92**, 4467-4471 (1995).
- 2 – Muraosa Y., Takahashi K., Yoshizawa M. and Shibahara S.: cDNA cloning of a novel protein containing two zinc-finger domains that may function as a transcription factor for the human heme-oxygenase-1-gene. *Eur. J. Biochem.* **235**, 471-479 (1996).
- 3 – Buyse I., Takahashi E. and Huang S.: Physical mapping of the retinoblasma-interacting zinc finger gene RIZ to D1S228 on chromosome 1p36. *Genomics* **34**, 119-121 (1996).
- 4 – Genuardi M., Tsihira H., Anderson D.E. and Saunders G.F.: Distal deletion of chromosome 1p in ductal carcinoma of the breast. *Am. J. Hum. Genet.* **45**, 73-82 (1989).
- 5 – Buyse I. and Huang S.: In vitro analysis of the E1A-homologous sequences of RIZ. *J. Virol.* **71**, 6200-6203 (1997).
- 6 – Huang S., Shao G., and Liu L.: The PR domain of the Rb-binding zinc finger protein RIZ1 is a protein binding interface and is related to the SET domain functioning in the chromatin-mediated gene expression. *J. Biol. Chem.* **273**, 15933-15939 (1998).
- 7 – Liu L., Shao G., Steele-Perkins G. and Huang S.: The retinoblasma interacting zinc finger gene RIZ produces a PR domain-lacking product through an internal promoter. *J. Biol. Chem.* **272**, 2984-2991 (1997).
- 8 – Xie M., Shao G., Buyse I. and Huang S.: The transcriptional repression mediated by the PR-domain zinc finger gene RIZ. *J. Biol. Chem.* **272**, 26360-26366 (1997).
- 9 – He L., Yu J.X., Liu L., Buyse I.M., Wang M.S., Yang Q.C., Nakagawara A., Brodeur G.M. and Huang S.: RIZ1, but not the alternative RIZ2 product of the same gene, is underexpressed in breast cancer and forced RIZ1 expression causes G2-M cell cycle arrest and/or apoptosis. *Cancer Res.* **58**, 4238-4244 (1998).
- 10 – Fears S., Mathieu C., Zeleznik-Le N., Huang S., Rowley J.D. and Nucifora G.: Intergenic splicing of MDS1 and EVII occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. *Proc. Natl. Acad. Sci. USA.* **93**, 1642-1647 (1996).
- 11 – Keller A.D. and Maniatis T.: Identification and characterization of a novel repressor of  $\beta$ -interferon gene expression. *Genes Dev.* **5**, 868-879 (1991).

- 12 – Turner C.A.Jr., Mack D.H. and Davis M.M.: Blimp-1, a novel zinc-finger containing protein that can drive the maturation of B-lymphocytes into immunoglobulin-secreting cells. *Cell*. **77**, 297-306 (1994).
- 13 – Huang S.: Blimp-1 is the murin homolog of the human transcriptional repressor PRDI-BF1. *Cell*. **78**, 9 (1994).
- 14 – Cui X., De Vivo I., Slany R., Myamoto A., Firestein R. and Cleary M.L.: Association of SET domain and myotubularin-related proteins modulates growth control. *Nat. Genet.* **18**, 331-337 (1998).
- 15 – Cardoso C., Timsit S., Villard L., Khrestchatisky M., Fontes M. and Colleaux L.: Specific interaction between the XNP/ATR-X gene product and the SET domain of the human EZH2 protein. *Hum. Mol. Genet.* **7**, 679-6844 (1998).
- 16 – Yang X.H. and Huang S.: PFM1 (PRDM4), a new member of the PR-domain family, maps to a tumor suppressor locus on human chromosome 12q23-q24.1 *Genomics*. **61**, 319-325 (1999).
- 17 – Trievel R.C., Beach B.M., Dirk L.M.A, Houtz R.L. and Hurley J.H.: Structure and catalytic mechanism of a SET domain protein methyltransferase. *Cell*. **111**, 91-103 (2002).
- 18 – Zhang X., Tamaru H., Khan S.I., Horton J.R., Keefe L.J., Selker E.U. and Cheng X.: Structure of the *neurospora* SET domain protein DIM-5, a histone H3 lysine methyltransferase. *Cell*. **111**, 117-127 (2002).
- 19 – Wilson J.R., Jing C., Walker P.A., Martin S.R., Howell S.A., Blackburn G.M., Gamblin S.J and Xiao B.: Crystal structure and functional analysis of the histone methyltransferase SET7/9. *Cell*. **111**, 105-115 (2002).
- 20 – Min J, Zhang X., Cheng X., grewal S.S., Xu R.: Structure of the SET domain histone lysine methyltransferase Clr4. *Nat. Struct. Biol.* **9**, 828-832 (2002).
- 21 – Jacobs S.A., Harp J.M., Devarakonda S., Kim Y., Rastinejad F. and Khorasanizadeh S.: The active site of the SET domain is constructed on a Knot. *Nat. Struct. Biol.* **9**, 833-838 (2002).
- 22 – Manzur K.L., Farooq A., Zeng L., Plotnikova O., Koch A.W, Zhou S. and M.M.: a dimeric viral SET domain methyltransferase specific to Lys27 of histone H3. *Nat. Struct. Biol.* **10**, 187-196 (2003).